The U.S. Supreme Court's recent decision to not hear CareDx's appeal marks a significant development in the ongoing false advertising litigation against Natera, Inc. This ruling effectively concludes a protracted legal battle, affirming previous judgments that denied CareDx monetary compensation. The dispute revolved around the alleged misleading promotion of Natera's Prospera kidney transplant test in comparison to CareDx's AlloSure test, a matter that had previously seen a jury award damages to CareDx before being overturned. This outcome underscores the complexities of legal precedent and the judiciary's role in resolving high-stakes corporate disagreements within the healthcare diagnostics sector.
U.S. Supreme Court Declines to Review CareDx's False Advertising Appeal Against Natera, Inc.
On June 1, as reported by Reuters, the United States Supreme Court made a pivotal decision by declining to consider an appeal lodged by CareDx. This appeal sought to challenge earlier court rulings in a false advertising dispute involving Natera, Inc. (NASDAQ:NTRA). The high court's refusal effectively maintains the lower court's decisions, which had previously withheld damages from CareDx related to claims concerning kidney transplant tests. The initial legal contention centered on allegations that Natera, Inc. had engaged in misleading promotional activities, specifically in its comparative advertising of the Prospera test against CareDx's AlloSure test. While the Supreme Court offered no specific rationale for its non-review, this action leaves intact the prior judicial determinations. In 2023, U.S. District Judge Colm Connolly had overturned a jury's nearly $45 million damages award to CareDx, citing a lack of evidence that Natera's statements had actually misled consumers, despite the jury's finding of false advertising. This judgment was subsequently upheld by the 3rd U.S. Circuit Court of Appeals. A representative for Natera expressed satisfaction with the final outcome of this litigation. CareDx had advocated for a legal presumption of deception in cases of "deliberately false" advertising, but Natera maintained that the appellate court appropriately applied established trial instructions. Natera, Inc. is a prominent diagnostics company, actively engaged in the research, development, and commercialization of genetic testing services.
This judicial outcome in the fiercely competitive healthcare diagnostics arena offers valuable insights into the intricate landscape of corporate litigation and regulatory oversight. It highlights the stringent evidentiary standards required to prove consumer deception in false advertising claims and the judiciary's cautious approach to overturning established lower court decisions. For companies operating in sectors characterized by rapid innovation and intense competition, this case serves as a stark reminder of the critical importance of transparent and accurate marketing practices. Beyond the immediate legal implications, the resolution of this dispute could influence future advertising strategies and compliance efforts within the diagnostics industry, potentially fostering a more rigorous adherence to truth in advertising and fair competition.